Date: Sep 09, 2015 Source: Company Data (
click here to go to the source)
Biomedical Advanced Research and Development Authority (BARDA) -- BARDA has been a major supporter of tecovirimat (aka ST-246®) over the last few years. BARDA has awarded SIGA a contract worth in excess of $400 million through Project BioShield funding for the delivery of 2 million courses of tecovirimat to the Strategic National Stockpile (SNS). Part of this contract covers advanced development of tecovirimat and includes additional options to be exercised at BARDA's discretion.
The National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID) -- NIAID has been a major supporter of SIGA antiviral countermeasure development, awarding approximately $47 million in funding since 2006.
Office of Biodefense Research Affairs (OBRA) -- In addition to administering the major contract supporting tecovirimat development, OBRA has provided access to animal models and preclinical testing capabilities.
Centers for Disease Control and Prevention (CDC) -- All of the in vitro and in vivo testing of tecovirimat against variola virus has been conducted at the CDC BSL-4 laboratories in Atlanta. In addition, SIGA worked closely with CDC scientists on the treatment of several emergency cases that were conducted under eINDs (emergency Investigational New Drug applications).
Department of Defense (DOD)
Several federal appropriations administered by the U.S. Department of the Army and the Defense Threat Reduction Agency have supported SIGA's programs.
The Defense Threat Reduction Agency (DTRA) -- DTRA has provided essential funding to enable the testing of tecovirimat in monkeypox and smallpox infected non-human primates under BSL-3 and BSL-4 conditions, respectively, as well as provided support for our broad-spectrum antiviral development.
The United States Army Medical Research Institute for Infectious Diseases (USAMRIID) -- SIGA has numerous ongoing projects with scientists at USAMRIID to test viral countermeasures against monkeypox, smallpox, and Ebola.
